Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model
Year: 2024
Type: article
DOI: 10.1002/ctm2.70101
Authors: Tian Zeng, Xiudi Yang, Yi Wang, Dijiong Wu, Weiying Feng, Ying Lu, Xiaoqiong Zhu, Lirong Liu, Mei Zhou, Li Zhang, Yanping Shao, Honglan Qian, Feng Zhu, Yu Chen, Dan Cao, Li Huang, Xiaoning Feng, Lili Chen, Gang Zhang, Jing Le, Weiguo Zhu, Yongming Xia, Yanxia Han, Yongqing Jia, Guoyan Tian, Hui Zhou, Linjuan Xu, Xiufeng Yin, Qinli Tang, Yuefeng Zhang, Guoli Yao, Xianghua Lang, Kaifeng Zhang, Xiujie Zhou, Junbin Guo, Jinming Tu, Jianzhi Zhao, Gongqiang Wu, Huiqi Zhang, Xiao Wu, Qiulian Luo, Lihong Cao, Binbin Chu, Wei Jiang, Haiying Wu, Liansheng Huang, Meiwei Hu, Muqing He, Jingjing Zhu, Hongyan Tong, Jie Jin, Jian Huang
Institutions: First Affiliated Hospital Zhejiang University, Ningbo University, Zhejiang Chinese Medical University, Shaoxing People's Hospital, Zhejiang University, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Shaoxing University, Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Zhoushan Hospital, Huzhou Central Hospital, Second Affiliated Hospital of Zhejiang University, Lishui City People's Hospital, Taizhou First People's Hospital, Jiaxing University, First Hospital of Jiaxing, Ningbo Medical Center Lihuili Hospital, Shaoxing Second Hospital, Affiliated Hospital of Hangzhou Normal University, Quzhou City People's Hospital, Sir Run Run Shaw Hospital, The First People's Hospital of Pinghu, Hangzhou Medical College, The First People's Hospital of Wenling, Dongyang People's Hospital, Ningbo University Affiliated Hospital, Zhejiang Shuren University, Tongde Hospital of Zhejiang Province
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,470
OpenAlex ID: W4404636806